PLAINSBORO, N.J., March 10, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (NASDAQ:IART), a leading global medical technology company, today announced that through its partnership with Buffalo Supply, it has received a five-year, $10.3 million contract with the U.S. Department of Defense (DoD), to provide greater access to both its Specialty Surgical Solutions and Orthopedics & Tissue Technology products. The contract is specified for the Defense Logistics Agency (DLA) Medical Electronic Catalogue (ECAT). The DLA purchases approximately $4.5 billion of medical material each year for DoD facilities around the world, as well as other U.S. federal agencies.
“We are delighted to be a part of the ECAT system. Integra’s products are used with great success in U.S. Military medical treatment facilities, and many have been integrated into medical procedures developed and applied by military surgeons practicing across the globe. ECAT provides a quicker and more efficient means for all U.S. Military medical treatment facilities to get access to our life-changing and, in many instances, life-saving technology, where and when they need it,” said Paul Gonsalves, Integra’s Chief Commercial Officer. “This contract offers Integra a greater opportunity to provide more of our medical technology and solutions to the brave men and women in uniform, worldwide.”
The ECAT contract includes a wide variety of Integra products designed to meet the ever-changing challenges faced by military clinicians when bringing life-saving care to troops who have suffered a wide range of battlefield injuries. These unique solutions include Integra® Dermal Regenerative Template (IDRT), the only FDA and PMA approved product for the treatment of third-degree burns and scar contractures, along with a multitude of other Regenerative Wound Care products used in the treatment of mild to severe soft tissue injuries.
“No one deserves access to better health care more than our active military personnel and veterans, and if in some small way we at Integra can make this a daily reality, then we can feel proud of who we are and what we do,” said Lou Cavallaro, Integra’s National Director, Government Accounts.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Company Investors Angela Steinway 609-936-2268 firstname.lastname@example.org Michael Beaulieu 609-936-2827 email@example.com Media Gianna Sabella 609-775-8553 firstname.lastname@example.org
Source:Integra LifeSciences Holdings Corporation